Update in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis

Abstract

Of all the possible complications associated with endoscopic retrograde cholangiopancreatography (ERCP), acute pancreatitis undoubtedly represents the heaviest burden for patients and healthcare professionals. The overall incidence, ranging from 3.5% to around 10%, and annual estimated costs exceeding $150 million in the USA should signal caution for everyone carrying out ERCP. In-depth knowledge of the risk factors and the pharmacological and endoscopic treatment options is required to avoid this adverse event. In this review, we evaluate the relevant data published in the literature since the appearance of the latest recommendations of the leading gastroenterological societies. Thus, we intend to provide a comprehensive and up-to-date overview of the factors to consider and possible interventions applicable before and after the intervention to prevent the development of post-ERCP pancreatitis.

Keywords Post-endoscopic retrograde cholangiopancreatography pancreatitis, prophylaxis, pancreatic stent, nonsteroidal anti-inflammatory drugs, fluid therapy

Ann Gastroenterol 2024; 37 (3): 266-279